AdvertisementAdvertise with NZME.
Stock Takes
Stock Takes: The big issues facing F&P Healthcare
F&P Healthcare's share price has held despite concerns about the US health sector.
Stock Takes: Why a2 is out of favour, and a role reversal for Fonterra
Private equity is seen as a likely buyer for Fonterra's consumer business.
Is this tech company the next Xero?
This freshly listed tech start-up is back by Sir Owen Glenn.
'NZ is in a tough patch': Why our economy is looking like the US during the GFC
Fisher Funds' Ashley Gardyne weighs in on how markets have performed.
Why is there such a dearth of companies listing on the NZX?
It has been months since the last listing on the NZ Stock Exchange.
How this NZ pharma firm prices drugs to avoid villain status
This NZ drug maker says it puts health above wealth.
‘A rounding error’: Why Govt’s $4b Budget boost doesn’t signal big spend-up
The no-frills Budget needs to focus on the basics.
Is it time to list Ports of Auckland on share market?
A new report has highlighted some problems with local government ownership.
Cost of Gabrielle and January floods will run into billions of dollars
Infometrics CEO Brad Olsen talks floods and reporting season.
Continuous Disclosure: High demand for Auckland Council bond and IPO warning
Whopper debt raising from Auckland Council.
Continuous Disclosure: Why are NZ companies flocking to the ASX?
What is happening on the markets this week.
Continuous Disclosure: Port of Tauranga, fund manager fees, bank dividends
The latest on the markets.
Continuous Disclosure: Could Metlifecare deal be start of something bigger?
Once Metlife is hoovered up, the Swedes could go even further.
How to protect your investments from coronavirus
Coronavirus proof your portfolio and prepare for more market volatility ahead.
Continuous Disclosure: How much the Kiwibank-BNZ deal could cost
A market listing would be lapped up by investors and KiwiSaver funds.
Continuous Disclosure: What made the naughty and nice list for investors in 2019
Experts share their best and worst moments of the year.
Continuous Disclosure: MET's mystery bidder, Moutter cashes in and Xero's $80 landmark
What's happening on the markets this week.